DuPont Oral TNF Inhibitor For Arthritis, Sustiva Successor Are In Phase II
DuPont Pharmaceuticals expects to file an NDA for an orally dosed TNF inhibitor in 2004, the company told analysts April 11.
DuPont Pharmaceuticals expects to file an NDA for an orally dosed TNF inhibitor in 2004, the company told analysts April 11.